ClinicalTrials.gg
CompletedNCT03559062Updated Feb 11, 2020Results posted

A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis

A Phase 3 interventional study of TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 27 sites in 9 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2020-02-11.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.

Enrollment
33rd of 43
67 · median 100
Started
2018
with 4 others
Phase 3
25 of 43
none open now
Registered
20th of 43
by date
Lead sponsor
39 of 43
Vertex Pharmaceuticals Incorporated

Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 33rd largest by enrollment, is one of 5 that started in 2018, is one of 25 in phase 3, and was the 20th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tezacaftor

tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tezacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This study will evaluate the efficacy of tezacaftor in combination with ivacaftor (TEZ/IVA) in participants with cystic fibrosis (CF) aged 6 through 11 years, who are homozygous for the F508del mutation (F/F) or heterozygous for F508del with an eligible residual function mutation (F/RF).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Homozygous for F508del or heterozygous for F508del and an RF mutation (as defined in the protocol).
  • Participants with ppFEV1 of ≥70 percentage points adjusted for age, sex, height.
  • Participants with a screening LCI2.5 result ≥7.5.
  • Participants who are able to swallow tablets.

Key Exclusion Criteria:

  • cirrhosis with or without portal hypertension.
  • Colonization with organisms associated with a more rapid decline in pulmonary status.
  • Solid organ or hematological transplantation.

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
67 participants (actual)

Study arms

  • Other
    Placebo

    Participants with genotype F/F received placebo matched to TEZ/IVA fixed dose combination (FDC) in the morning and placebo matched to IVA in the evening for 8 weeks.

    Drug: Placebo

  • Experimental
    TEZ/IVA

    Participants with genotype F/F received TEZ/IVA FDC in the morning and IVA in the evening for 8 weeks. Participants with genotype F/RF received TEZ/IVA FDC and placebo matched to IVA in the morning and IVA in the evening for 8 weeks.

    Drug: TEZ/IVA · Drug: IVA · Drug: Placebo

  • Experimental
    Ivacaftor

    Participants with genotype F/RF received placebo matched to TEZ/IVA FDC in the morning and IVA in morning and evening for 8 weeks.

    Drug: IVA · Drug: Placebo

Interventions

  • DrugTEZ/IVA

    Drug pages: Tezacaftor · Ivacaftor

    Participants weighing \<40 kg received TEZ 50 mg/IVA 75 mg FDC tablet and those weighing ≥40 kg received TEZ 100 mg/IVA 150 mg FDC tablet.

    Also known as: VX-661/VX-770, tezacaftor/ivacaftor fixed dose combination

  • DrugIVA

    Participants weighing \<40 kg IVA 75 mg tablet and those weighing ≥40 kg received IVA 150 mg tablet.

    Also known as: VX-770, ivacaftor

  • DrugPlacebo

    Placebo matched to TEZ/IVA FDC

  • DrugPlacebo

    Placebo matched to IVA

06

What researchers measure

Primary outcomes

  1. Absolute Change in Lung Clearance Index 2.5 (LCI2.5) Through Week 8

    LCI2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.

    Time frame: From baseline through Week 8

Secondary outcomes

  1. Absolute Change in Sweat Chloride At Week 8

    Sweat samples were collected using an approved collection device.

    Time frame: From baseline at Week 8

  2. Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 8

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: From baseline through Week 8

  3. Safety and Tolerability as Assessed Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) up to Safety Follow-up Visit

    Time frame: From first dose of study drug up to safety follow-up visit (up to Week 12)

07

Results

Posted Feb 11, 2020

Participant flow

Participant flow — Overall Study
MilestonePlaceboTEZ/IVAIvacaftor
Started10543
Completed10533
Not completed010
Withdrew: Other010

Outcome measures

PrimaryAbsolute Change in Lung Clearance Index 2.5 (LCI2.5) Through Week 8

LCI2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.

Time frame:
From baseline through Week 8
Reported as:
Least squares mean · lung clearance index
Absolute Change in Lung Clearance Index 2.5 (LCI2.5) Through Week 8
lung clearance indexTEZ/IVA
Absolute Change in Lung Clearance Index 2.5 (LCI2.5) Through Week 8-0.51 ± 0.11
Statistical analysis
  • TEZ/IVA · Mixed-effects model for repeated measure · p = <0.0001
SecondaryAbsolute Change in Sweat Chloride At Week 8

Sweat samples were collected using an approved collection device.

Time frame:
From baseline at Week 8
Reported as:
Least squares mean · millimole per liter (mmol/L)
Absolute Change in Sweat Chloride At Week 8
millimole per liter (mmol/L)TEZ/IVA
Absolute Change in Sweat Chloride At Week 8-12.3 ± 1.5
Statistical analysis
  • TEZ/IVA · Mixed-effects model for repeated measure · p = <0.0001
SecondaryAbsolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 8

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
From baseline through Week 8
Reported as:
Least squares mean · units on a scale
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 8
units on a scaleTEZ/IVA
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 82.3 ± 1.2
Statistical analysis
  • TEZ/IVA · Mixed-effects model for repeated measure · p = 0.0546
SecondarySafety and Tolerability as Assessed Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) up to Safety Follow-up Visit
Time frame:
From first dose of study drug up to safety follow-up visit (up to Week 12)
Reported as:
Count of participants · Participants
Safety and Tolerability as Assessed Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) up to Safety Follow-up Visit
ParticipantsPlaceboTEZ/IVAIvacaftor
Participants with AEs8412
Participants with SAEs000

Adverse events

Collected over From first dose of study drug up to safety follow-up visit (up to Week 12). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/10 (0%)0/10 (0%)8/10 (80%)
TEZ/IVA0/54 (0%)0/54 (0%)31/54 (57.4%)
Ivacaftor0/3 (0%)0/3 (0%)2/3 (66.7%)
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPlaceboTEZ/IVAIvacaftor
Arthropod biteInjury, poisoning and procedural complications0/100/541/3
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/103/541/3
BlisterSkin and subcutaneous tissue disorders0/100/541/3
ImpetigoInfections and infestations0/100/541/3
Upper respiratory tract infectionInfections and infestations0/100/541/3
Viral upper respiratory tract infectionInfections and infestations0/100/541/3
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations2/103/540/3
CoughRespiratory, thoracic and mediastinal disorders1/109/540/3
HeadacheNervous system disorders1/108/540/3
Productive coughRespiratory, thoracic and mediastinal disorders1/107/540/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboTEZ/IVAIvacaftorTotal
Mean9.0 ± 1.78.5 ± 1.79.0 ± 1.78.6 ± 1.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTEZ/IVAIvacaftorTotal
Female629237
Male425130
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTEZ/IVAIvacaftorTotal
Hispanic or Latino0101
Not Hispanic or Latino1046359
Unknown or Not Reported0707
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTEZ/IVAIvacaftorTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0101
White1051364
More than one race0000
Unknown or Not Reported0202
Lung Clearance Index 2.5 (LCI2.5)
Lung Clearance Index 2.5 (LCI2.5)(lung clearance index)PlaceboTEZ/IVAIvacaftorTotal
Mean9.67 ± 1.659.56 ± 2.068.60 ± 1.409.54 ± 1.97
08

Study locations

27 sites
  • Hunter Medical Research Institute (HMRI)
    New Lambton Heights, Australia
  • Princess Margaret Hospital for Children
    Perth, Australia
  • Lady Cilento Children's Hospital
    South Brisbane, Australia
  • The Children's Hospital at Westmead
    Westmead, Australia
  • Universitair Ziekenhuis Brussel - Campus Jette
    Brussels, Belgium
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Leuven, Belgium
  • University of Copenhagen Rigshospitalet
    Copenhagen, Denmark
  • Groupe Hospitalier Pellegrin - Hôpital des Enfants
    Bordeaux Cedex, France
  • Hôpital Necker - Enfants Malades
    Paris, France
  • Universitaetsklinikum Essen
    Essen, Germany
  • Klinikum der Johann Wolfgang Goethe-Universitaet
    Frankfurt, Germany
  • Universitaetsklinikum Giessen und Marburg GmbH Standort Giessen
    Giessen, Germany
  • Medizinische Hochschule Hannover
    Hannover, Germany
  • Universitaetsklinikum Heidelberg
    Heidelberg, Germany
  • Universitaetsklinikum Jena
    Jena, Germany
  • Universitaetsklinikum Koeln
    Koeln, Germany
  • Universitaetsklinikum Tuebingen
    Tuebingen, Germany
  • Our Lady's Children's Hospital
    Dublin, Ireland
  • University Hospital Limerick
    Limerick, Ireland
  • Klinika Mukowiscydozy, Oddział Chorób Płuc SZP ZOZ
    Dziekanow Lesny, Poland
  • Inselspital - Universitaetsspital Bern
    Bern, Switzerland
  • Kinderspital Zuerich
    Zuerich, Switzerland
  • Royal Hospital for Sick Children
    Edinburgh, United Kingdom
  • Leeds General Infirmary
    Leeds, United Kingdom
  • Royal Brompton Hospital
    London, United Kingdom
  • Nottingham University Hospital City Campus
    Nottingham, United Kingdom
  • Southampton General Hospital
    Southampton, United Kingdom
09

References and documents

Publications

  • Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. PubMed 33331662 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Dec 2018, 7 months.

Results were first posted in Feb 2020, 1 year 1 month after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 7 months is below that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2018
First posted
Jun 15, 2018
StartActual
May 17, 2018
Primary completionActual
Dec 21, 2018
CompletionActual
Dec 21, 2018
Results first posted
Feb 11, 2020
Last update
Feb 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03559062
Responsible party
Sponsor
First posted
Jun 15, 2018
Start date
May 17, 2018
Primary completion
Dec 21, 2018
Completion
Dec 21, 2018
Results posted
Feb 11, 2020
Last update
Feb 11, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tezacaftor · Ivacaftor

Start the discussion